A catalogue of studies being delivered within Avon and Wiltshire Mental Health Partnership NHS Trust (AWP), compiled from the National Institute of Health Research (NIHR)
Below are some studies that AWP would like to offer people the opportunity to take part in. If you are interested please call us on 0117 378 4266 or email email@example.com.
If there are no studies listed that you are interested in but you would like to hear about others we welcome you to get in touch.
Anxiety & Depression Studies
GLAD – Genetic Links to Anxiety & Depression
The GLAD Study is a project set up to explore risk factors in individuals who have experienced depression and/or anxiety, including those with a diagnosis of bipolar disorder, OCD, or related disorders, at any time in their lives.
It aims to better understand depression and anxiety in order to find and develop more effective treatments. The GLAD Study is also part of the NIHR BioResource, which is a library of information about people's health aiming to support research in both physical and mental health.
To take part in the GLAD Study, you must:
- Have experienced symptoms of anxiety and/or depression during your life
- Be aged 16 and above
- Live in the UK
The GLAD Study enrolment process consists of four steps:
- Register on the website www.gladstudy.org.uk and read the Information Sheet
- Providing consent (please put AWP as where you heard about the study
- Completing a questionnaire
- Providing a saliva sample
Bipolar & Psychosis Studies
PREFER - Patient Preferences for Voice-Hearing Therapies
PREFER is a large national survey with patients who hear voices.
We are asking patients to tell us about their therapy preferences like:
• when and where should therapy take place
• what should therapy involve and what it should aim to improve?
If you are at least 16 and have heard voices for at least 6 months, we would like to invite you to take part by completing the questionnaire, which:
• is done with a researcher
• online, on a phone, or on paper
• and should take about 45minutes
The findings will be used to inform researchers and clinicians to help them develop and offer the types of therapies that patients really want.
PPiP2 – Prevalence of neuronal cell surface antibodies in patients with psychotic illness
This study aims to understand if some cases of psychosis are caused by immune system problems in some people. The immune system normally controls our ability to fight infection, but if the immune system goes wrong it may cause diseases called 'autoimmune' diseases. It is possible to diagnose some of these immune diseases using blood tests, and treatments are available if a disease is found.
To be involved in this study you will be asked to give a blood sample. The appointment may take up to one hour of your time. You will receive £10 for the time you have spent taking part in the study. If from the blood test we find that you test positive for a disease of the immune system, the study team will contact your clinical team, who, in turn, will contact you with potential treatment options. To take part in the study you must be between 18-70 years old and be experiencing some symptoms of psychosis.
GameChange – Virtual reality treatment for people with psychosis
The GameChange Study is for people experiencing psychosis whose fears have caused them to withdraw to such an extent that everyday tasks – such as getting on a bus, doing the shopping or speaking to other people – are a challenge. We want to help people go into everyday situations feeling more confident, calmer, and in control.
GameChange is an easy to use Virtual Reality (VR) programme. It allows a person to practise, at their own pace, being in computer simulations which replicate everyday situations (like a video game). By putting on a headset, a person sees, hears, and can move around the computer simulation. The confidence gained from practice in VR carries over into the real world. The purpose of this study is to see whether the VR therapy is helpful for people who get anxious in everyday situations. The VR therapy is offered as additional support and the standard care received from the NHS will not change.
AWP contacts for more info:
Kate Chapman firstname.lastname@example.org
Kira Williams email@example.com
Charlotte Way firstname.lastname@example.org
Perinatal Mental Health Studies
ESMI-II - The EffectivenesS and cost effectiveness of community perinatal Mental health servIces: An interview study
The ESMI-II study aims to find out what mother's and their significant source of support's experiences of their perinatal mental health care provided by Community Perinatal Mental Health Teams.
The research will examine what part of their care they found most helpful for them, who they interacted with and also what was not so helpful. With an interested in who is accessing these services and what aspects of the service work for whom. The interview will last up to 90 minutes.
The study will now also be looking at what the impact of COVID-19 has been on how women experience service delivery and on their overall wellbeing.
The ESMI-II study will also invite key providers within Community Perinatal Mental Health Teams to take part in interviews (90 mins) to collect information to:
- provide insight into how services are set up and deliver perinatal mental health care
- better understand how services overcome barriers and facilitate access to treatment across the care pathway
- identify acceptable observation methods used to look at mother-infant interactions and the impact of such interventions
Other Mental Health Studies
ESCAPE 2 - intEgrating Smoking Cessation treatment As part of routine Psychological care for dEpression and anxiety
This RCT aims to develop a bespoke smoking cessation intervention and then to examine its feasibility and acceptability in community mental health settings.
This study has two stages:
- Stage 1 – Interviews with staff (IAPT) and patients will be held to aid with the design of the intervention.
- Stage 2 – 140 patients randomised on a 1:1 basis to receive the new intervention or treatment as usual.
Kingshill Research Centre (KRC) Studies
Contact Kingshill Research Centre for more information email@example.com or 01793 327 954
GAIN Trial (Cortexyme Study) - A Randomised, Double-blind, Placebo-controlled Study of COR388 HCl in Subjects with Alzheimer's Disease
There is a growing body of research showing that the bacteria often found in gum disease (P. gingivalis) can enter the the bloodstream, and infect the brain. When this bacteria enters the brain and releases toxic proteins (gingipains), it is thought that it can cause Alzheimer's. By stopping the bacteria from releasing toxic proteins, it is thought that the drug could prevent the progression of Alzheimer's disease.
The study is 54 weeks in duration. We are happy to see people with an MMSE score between 12-22, aged between 55-80.
Cognetivity – Cognitive assessment via Artificial Intelligence (AI)
The aim of the study is to validate a new computerised artificial intelligence (AI) assisted cognitive assessment test in comparison to cognitive tests that are used to aid diagnosis.
We are recruiting healthy volunteers, mild cognitive impairment and Alzheimer's patients who have recently been diagnosed (within 12 months), with an age range is 55-90.
The study will involve one visit (approx 2 hours) to Kingshill Research Centre to complete traditional paper and pen memory assessments and the AI test. Participants will be compensated for their time with a £30 high street voucher.